Asia
Eisai has received a New Drug Approval for its in-house developed anticancer agent Halaven for use in the treatment of patients with locally advanced or metastatic breast cancer, previously treated with at least two prior chemotherapy regimens, including an anthracycline and a taxane, from the China National Medical Products Administration.
With the latest major Phase 3 failure of Biogen and Eisai’s beta-amyloid-targeting antibody drug aducanumab, researchers are increasingly turning to other drug targets for Alzheimer’s disease.
There’s been quite a few small and mid-sized deals announced today. Let’s take a look at four of them.
Patented botanical formula LCS103 shows an 80% decrease in bladder cancer recurrence rate in a recent case series clinical trial
Largest off-the-shelf diploid KO library, over 2,800 cell lines
A list of the top 10 biotech IPOs from January to the end of June this year shows significant involvement in the Hong Stock exchange, with five companies based in China, and one, Frontage Holdings, operating in both the U.S. and China.
In a deal-making spree, Genentech will team up with the small companies to take on various diseases, including multiple sclerosis.
Four years ago, Takeda Pharmaceutical Company and The Center for iPS Cell Research and Application (CiRA) at Kyoto University established a 10-year joint research program. Today, the organizations made an announcement.
In November 2018, Chinese researcher He Jiankui announced he had used CRISPR gene editing to modify the CCR5 genes in the embryos of seven Chinese couples. This was met by widespread condemnation, investigations and a call for a global moratorium against that type of research.
Todos Medical Ltd., a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, such as Alzheimer’s disease, announced that it has launched a roadshow for a public offering of up to $7,000,000 of units.
PRESS RELEASES